| | | Bare bones report:
CNSP had a 50:1 reverse split, which is rather dire.
finance.yahoo.com
“HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024.
Beginning on June 5, 2024, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H300. The reverse stock split is primarily intended to increase the Company's per share trading price and bring the Company into compliance with the Nasdaq's listing requirement regarding minimum share price.”
Actually, if do a web search on
“recent biotech reverse stock splits”
For the last week (or pick your date range,) it seems to be a popular trend these days.
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 5/31/24
| 6/7/24
|
|
|
|
|
|
|
|
| YTD
| 12/31/2023
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| $2,652.05
| 2.4%
| $14,134.45
|
|
|
|
|
|
|
|
| ^NBI
| $2,302.63
| 2.3%
| $3,000.77
|
|
|
|
|
|
|
|
| ^SPSIBI
| $2,574.68
| 2.6%
| $2,230.02
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| NVAX
| 65.4%
| VKTX
| -33.7%
| NVAX
| 278.5%
| CNSP
| -92.0%
| LRMR
| 34.9%
| CBUS
| -18.4%
| JSPR
| 210.8%
| GLYC
| -89.1%
| REPL
| 31.2%
| JSPR
| -18.3%
| VKTX
| 200.9%
| AMLX
| -88.0%
| AFMD
| 28.6%
| TNYA
| -17.6%
| CU6.AX
| 164.1%
| PACB
| -79.5%
| TWST
| 23.2%
| OCUL
| -17.0%
| PYXS
| 111.1%
| RVNC
| -69.3%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| -$1,108.37
| $467.64
| TRACE I11
|
| $4,931.88
| -$2,837.56
| TECHNETIUM
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - ALONER (4)
| $4,683.85
| $2,109.17
| -$5,298.45 (13)
| 1 - BULBAMAN (1)
| $73,798.83
| ——
| $71,568.81
| -$4,528.94 (14)
| 2 - TOMATO (10)
| $3,384.30
| $809.61
| $30,534.62 (3)
| 2 - ERIKOTTO (2)
| $33,181.52
| $40,617.32
| $30,951.49
| $799.01 (6)
| 3 - NOTABOT (13)
| $3,135.69
| $561.01
| -$1,215.09 (8)
| 3 - TOMATO (4)
| $30,534.62
| $43,264.21
| $28,304.60
| $3,384.30 (2)
| 4 - DEW_DILIGENCE (6)
| $1,732.96
| -$841.73
| $9,318.60 (5)
| 4 - BLADERUNNER (3)
| $24,510.07
| $49,288.77
| $22,280.04
| -$7,290.49 (16)
| 5 - A. J. MULLEN (7)
| $1,717.57
| -$857.11
| -$23,287.53 (17)
| 5 - DEW_DILIGENCE (6)
| $9,318.60
| $64,480.23
| $7,088.58
| $1,732.96 (4)
| 6 - ERIKOTTO (2)
| $799.01
| -$1,775.67
| $33,181.52 (2)
| 6 - JACK HARTMANN (5)
| $6,776.92
| $67,021.91
| $4,546.90
| -$1,658.13 (10)
| 7 - DART LANZER (14)
| $591.31
| -$1,983.37
| -$3,797.26 (11)
| 7 - TRACE I11 (10)
| -$793.08
| $74,591.91
| -$3,023.10
| $467.64 (9)
| 8 - JR_95 (8)
| $582.18
| -$1,992.51
| -$18,869.47 (15)
| 8 - NOTABOT (12)
| -$1,215.09
| $75,013.92
| -$3,445.12
| $3,135.69 (3)
| Top Portfolios’ Contents
| Top Recent Performance Portfolio (ALONER)
| Top YTD Performance Portfolio (BULBAMAN)
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| ACRS
| 5.00%
| 5.1% | -3.8%
| -$190.48
| -$95.24
| 20.8%
| CU6.AX
| 20.00%
| 30.4% | 164.1%
| $32,811.25
| $568.88
| 1.9%
| AFMD
| 20.00%
| 20.7% | -1.8%
| -$352.00
| $5,728.00
| 5.1%
| CYTH
| 10.00%
| 4.6% | -20.8%
| -$2,075.47
| -$125.79
| 12.6%
| CDTX
| 20.00%
| 17.1% | -19.1%
| -$3,828.72
| $188.92
| 6.2%
| LRMR
| 10.00%
| 12.1% | 110.8%
| $11,076.92
| $3,494.51
| 4.7%
| CLSD
| 5.00%
| 5.5% | 4.3%
| $213.68
| -$769.23
| 19.2%
| PMN
| 10.00%
| 8.9% | 53.9%
| $5,391.30
| -$626.09
| 6.5%
| CRVS
| 20.00%
| 24.4% | 15.3%
| $3,068.18
| -$1,477.27
| 4.3%
| SNGX
| 10.00%
| 1.8% | -68.9%
| -$6,891.45
| -$1,101.97
| 32.2%
| KZIA
| 20.00%
| 12.0% | -43.2%
| -$8,646.19
| -$477.82
| 8.8%
| TCON
| 10.00%
| 1.9% | -67.4%
| -$6,744.72
| -$399.77
| 30.7%
| MRNA
| 5.00%
| 8.0% | 51.8%
| $2,592.26
| $425.34
| 13.2%
| TLX.AX
| 15.00%
| 14.4% | 67.3%
| $10,102.03
| -$1,284.97
| 4.0%
| TWST
| 5.00%
| 7.2% | 36.9%
| $1,844.82
| $1,161.15
| 14.6%
| VKTX
| 15.00%
| 26.0% | 200.9%
| $30,128.96
| -$5,053.73
| 2.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
